KBC Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

KBC Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98K	Hold	2,941	–	–	﹤0.01%	1436
2026 Q1	$62K	Hold	2,941	–	–	﹤0.01%	1576
2025 Q4	$68K	Hold	2,941	–	–	﹤0.01%	1511
2025 Q3	$88K	Hold	2,941	–	–	﹤0.01%	1342
2025 Q2	$107K	Sell	2,941 -755	-20%	-$27.2K	﹤0.01%	1161
2025 Q1	$134K	Sell	3,696 -57,314	-94%	-$2.38M	﹤0.01%	1313
2024 Q4	$2.57M	Buy	61,010 +58,442	+2,276%	+$2.9M	0.01%	648
2024 Q3	$143K	Buy	2,568 +506	+25%	+$25.8K	﹤0.01%	1083
2024 Q2	$85K	Buy	2,062 +478	+30%	+$20.4K	﹤0.01%	1266
2024 Q1	$74K	Hold	1,584	–	–	﹤0.01%	1300
2023 Q4	$76K	Hold	1,584	–	–	﹤0.01%	1237
2023 Q3	$56K	Buy	+1,584	New	+$62.8K	﹤0.01%	1354

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

KBC Group's RARE Position: Q2 2026 in Review

KBC Group held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 2,941 shares worth $98K. The position accounts for ﹤0.01% of the portfolio, ranked #1436.

KBC Group first reported a position in RARE in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.57M in Q4 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

KBC Group held 2,941 shares of Ultragenyx Pharmaceutical worth $98K as of Q2 2026.
KBC Group left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1436 holding.
KBC Group first reported a position in Ultragenyx Pharmaceutical in Q3 2023 and has held it in 12 quarters since.
KBC Group's Ultragenyx Pharmaceutical position peaked at $2.57M in Q4 2024.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.